Companies › Zhejiang Haichang Biotech
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| WGI-0301 Antisense oligonucleotide complementary to Akt-1 mRNA | AKT1 | Phase 2 | Advanced Hepatocellular Carcinoma (HCC) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06309485 | WGI-0301 | Phase 2 | Advanced Hepatocellular Carcinoma (HCC) | Oncology | Dec 2026 |
AstraZeneca Merck & Co. (MSD) Roche Laekna Alterome Therapeutics Atavistik Bio
Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.